Australian multi‐center experience outside of the Sydney Melanoma Unit of isolated limb infusion chemotherapy for melanoma

Abstract

In this, to date, largest multi-center study of ILI for melanoma the results are comparable to other reports and demonstrate that ILI can be widely implemented and safely applied across tertiary referral centers.

Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies

“…Comparing ILP/ILI patients diagnosed with melanoma to those with STS, the melanoma patients were slightly older (mean 64 years for melanoma and 59 years for STS), consistent with previous reports of age at the time of procedure for each disease . The mean LOS (4.8 days) following ILP/ILI for melanoma in the current study was most consistent with what is reported in the literature for ILI .…”

“…Comparing ILP/ILI patients diagnosed with melanoma to those with STS, the melanoma patients were slightly older (mean 64 years for melanoma and 59 years for STS), consistent with previous reports of age at the time of procedure for each disease. [7][8][9][10]12,13,18,37,[39][40][41] The mean LOS (4.8 days) following ILP/ILI for melanoma in the current study was most consistent with what is reported in the literature for ILI. 42,43 The mean LOS for the STS patients who underwent ILP/ILI was slightly longer (7.0 days), and may suggest a higher proportion of patients undergoing ILP, which is typically associated with a longer LOS.…”

“…OR rates of 70%‐90% and CR rates up to 60%‐70% are typically achieved with ILP for melanoma ITM . ILI performed for melanoma is associated with OR rates of 60%‐80% and CR rates of 30%‐40% . Despite generally lower reported response rates, ILI may be able to achieve similar local progression‐free survival rates as ILP .…”

“…and CR rates of 30%-40%. 11,[40][41][42]48,49 Despite generally lower reported response rates, ILI may be able to achieve similar local progression-free survival rates as ILP. 11 20,21,29 whereas ILP/ILI would not be restricted to certain patient populations.…”

Patients with in‐transit melanoma metastases have comparable survival outcomes following isolated limb infusion or intralesional PV‐10—A propensity score matched, single center study

“…4 ILI has been extensively investigated for unresectable recurrent melanoma within large, randomized prospective studies. [5][6][7] Complete and partial response (PR) rates have been consistently reported between 24% to 38% and 22% to 40%, respectively, with median overall survival (OS) periods of up to 44 months. 8,9 Predictors of response to ILI using local data have also been described by Barbour et al 10 More recently, intralesional Rose Bengal (PV-10) has been studied for locoregionally advanced and metastatic melanoma.…”